Triplet therapy versus androgen receptor pathway inhibitor–doublet therapy in metastatic castration-sensitive prostate cancer: a real-world multicenter retrospective comparison

Triplet therapy significantly prolonged CRPC-FS compared with ARPI-doublet therapy in patients with de novo mCSPC, particularly among those with high-volume disease. However, this benefit was accompanied by higher toxicity, underscoring the need to balance efficacy with safety. Longer follow-up is required to determine impacts on PFS2, cancer-specific survival, and overall survival.